X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
idelalisib (390) 390
index medicus (228) 228
ibrutinib (179) 179
humans (175) 175
oncology (152) 152
hematology (121) 121
chronic lymphocytic leukemia (117) 117
rituximab (100) 100
chronic lymphocytic-leukemia (99) 99
open-label (75) 75
leukemia, lymphocytic, chronic, b-cell - drug therapy (73) 73
cll (70) 70
cancer (64) 64
leukemia (63) 63
venetoclax (63) 63
male (59) 59
pi3k (59) 59
female (58) 58
aged (53) 53
inhibitor (52) 52
lymphomas (48) 48
middle aged (48) 48
pharmacology & pharmacy (47) 47
antineoplastic agents - therapeutic use (45) 45
lymphoma (45) 45
animals (39) 39
treatment outcome (39) 39
hemic and lymphatic diseases (37) 37
initial therapy (37) 37
phosphatidylinositol 3-kinases - antagonists & inhibitors (36) 36
antineoplastic agents - pharmacology (35) 35
cal-101 (35) 35
care and treatment (35) 35
chemotherapy (35) 35
follicular lymphoma (35) 35
adult (34) 34
b-cell receptor (34) 34
quinazolinones - therapeutic use (33) 33
survival (33) 33
aged, 80 and over (32) 32
purines - therapeutic use (32) 32
fludarabine (31) 31
ofatumumab (30) 30
previously untreated patients (30) 30
quinazolinones - pharmacology (30) 30
therapy (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
cyclophosphamide (29) 29
medicine & public health (29) 29
antineoplastic agents - adverse effects (28) 28
chronic lymphatic leukemia (28) 28
leukemia, lymphocytic, chronic, b-cell - pathology (28) 28
molecular targeted therapy (27) 27
obinutuzumab (27) 27
purines - pharmacology (27) 27
p110-delta (26) 26
pathway (26) 26
protein kinase inhibitors - therapeutic use (26) 26
apoptosis (24) 24
article (24) 24
patients (24) 24
phosphoinositide 3-kinase (24) 24
chronic lymphocytic leukaemia (23) 23
prognosis (23) 23
cell line, tumor (22) 22
signal transduction - drug effects (22) 22
phase-ii trial (20) 20
protein kinase inhibitors - pharmacology (20) 20
analysis (19) 19
cell biology (19) 19
chemistry, medicinal (19) 19
kinases (19) 19
non-hodgkin-lymphoma (19) 19
purines - administration & dosage (19) 19
pyrimidines - therapeutic use (19) 19
quinazolinones - administration & dosage (19) 19
targeted therapy (19) 19
lenalidomide (18) 18
leukemia, lymphocytic, chronic, b-cell - mortality (18) 18
mice (18) 18
purines - adverse effects (18) 18
quinazolinones - adverse effects (18) 18
activation (17) 17
chemoimmunotherapy (17) 17
class i phosphatidylinositol 3-kinases - antagonists & inhibitors (17) 17
hematology, oncology and palliative medicine (17) 17
immunotherapy (17) 17
leukemia, lymphocytic, chronic, b-cell - genetics (17) 17
lymphocytes b (17) 17
phosphatidylinositol 3-kinase (17) 17
pi3k-delta (17) 17
treatment-naive (17) 17
antineoplastic agents - administration & dosage (16) 16
apoptosis - drug effects (16) 16
combination (16) 16
enzyme inhibitors - pharmacology (16) 16
lymphatic leukemia (16) 16
minimal residual disease (16) 16
pyrazoles - therapeutic use (16) 16
review (16) 16
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (377) 377
French (5) 5
Spanish (5) 5
Czech (4) 4
Polish (3) 3
Turkish (2) 2
Croatian (1) 1
German (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Surgical Pathology, ISSN 0147-5185, 12/2015, Volume 39, Issue 12, pp. 1653 - 1660
Journal Article
American Journal of Surgical Pathology, ISSN 0147-5185, 12/2015, Volume 39, Issue 12, pp. 1661 - 1667
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 05/2017, Volume 28, Issue 5, pp. 1050 - 1056
Background: Ibrutinib, idelalisib, and venetoclax are approved for treating CLL patients in the United States. However, there is no guidance as to their... 
ibrutinib | kinase inhibitor | CLL | idelalisib | venetoclax | THERAPY | MANAGEMENT | ONCOLOGY | OUTCOMES | ATRIAL-FIBRILLATION | Index Medicus
Journal Article
Haematologica, ISSN 0390-6078, 04/2018, Volume 103, Issue 5, pp. 874 - 879
Clinical trials that led to ibrutinib's approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of... 
CHRONIC LYMPHOCYTIC-LEUKEMIA | THERAPY | HEMATOLOGY | IDELALISIB | Index Medicus
Journal Article
by Cheng, S and Guo, A and Lu, P and Ma, J and Coleman, M and Wang, YL
LEUKEMIA, ISSN 0887-6924, 04/2015, Volume 29, Issue 4, pp. 895 - 900
The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has produced remarkable clinical response in chronic lymphocytic leukemia (CLL) and mantle cell... 
BCR | EARLY EVENTS | SYK | ONCOLOGY | IDELALISIB | TYROSINE KINASE | BTK | PROLIFERATION | HEMATOLOGY
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2019, Volume 37, Issue 11, pp. 932 - 932
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 10/2015, Volume 56, Issue 10, pp. 2779 - 2786
Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood... 
phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor | transaminitis | colitis | pneumonitis | Idelalisib | diarrhea | Idelalisib, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor | phosphatidylinositol 3-kinase delta (PI3K) inhibitor | CAL-101 | DELTA | P110-DELTA | PI3K | ONCOLOGY | INHIBITOR | HEMATOLOGY | SUBUNIT | Index Medicus | Reviews | Review
Journal Article
TURKISH JOURNAL OF HEMATOLOGY, ISSN 1300-7777, 03/2019, Volume 36, pp. 15 - 16
Journal Article
CANCER, ISSN 0008-543X, 08/2018, Volume 124, Issue 16, pp. 3455 - 3456
Journal Article
Annals of Gastroenterology, ISSN 1108-7471, 2016, Volume 29, Issue 2, pp. 233 - 235
Idelalisib is an oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, approved by FDA since July 2014 for the treatment of relapsed follicular B-cell... 
Diarrhea | Enterocolitis | Idelalisib | enterocolitis | diarrhea | Case Report
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2016, Volume 59, Issue 19, pp. 9228 - 9242
Aberrant signaling of phosphoinositide 3-kinase delta (PI3K delta) has been implicated in numerous pathologies including hematological malignancies and... 
B-CELLS | CHEMISTRY, MEDICINAL | PI3K-DELTA | CAL-101 | AUTOIMMUNITY | IDELALISIB | PI3 KINASE | MECHANISMS | ARTHRITIS | CANCER | SELECTIVITY
Journal Article
International Journal of Biochemistry and Cell Biology, ISSN 1357-2725, 11/2019, Volume 116, p. 105615
Although conventional therapeutic approaches have brought remarkable advantages for the treatment of breast cancer (BC), drug-resistance still remains as a... 
Arsenic trioxide (ATO) | Breast cancer | PI3K signaling pathway | BKM120 (Buparlisib) | CAL-101 (Idelalisib)
Journal Article
BLOOD, ISSN 0006-4971, 02/2018, Volume 131, Issue 8, pp. 888 - 898
Duvelisib (IPI-145) is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K)-delta/gamma isoforms currently in clinical development. PI3K-delta/gamma... 
P110-DELTA | MULTICENTER | B-CELL | RESPONSE CRITERIA | IDELALISIB | MACROPHAGES | BRENTUXIMAB VEDOTIN | RESISTANCE | PI3K-GAMMA | HEMATOLOGY | VORINOSTAT | Lymphoid Neoplasia
Journal Article
The Lancet Haematology, ISSN 2352-3026, 02/2019, Volume 6, Issue 2, pp. e65 - e66
Journal Article
Blood, ISSN 0006-4971, 12/2018, Volume 132, Issue 23, pp. 2422 - 2424
In this issue of Blood, Flinn et al report the final results of the phase 3 registration trial DUO,(1) which compared the novel PI3K delta,gamma inhibitor... 
HEMATOLOGY | IDELALISIB | CHRONIC LYMPHOCYTIC-LEUKEMIA
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.